



(<https://survey.biofrontera.com/>) (<https://survey.biofrontera.com/en>)
 (<https://survey.biofrontera.com/en>)

ALA-BCC-CT013 - RECRUITMENT COMPLETE

This clinical trial aims to study a new investigational treatment for superficial basal cell cancer in the US.

ADDITIONAL INFORMATION ABOUT THIS TRIAL

([HTTPS://WWW.CLINICALTRIALS.GOV/CT2/SHOW/NCT03573401?TERM=ALA-BCC-CT013&RANK=1](https://www.clinicaltrials.gov/ct2/show/NCT03573401?term=ALA-BCC-CT013&rank=1))

ALA-ACV-CT014 - RECRUITMENT COMPLETE

This clinical trial aims to test a new investigational treatment for moderate to severe Acne vulgaris in the face. The study is conducted in the US.

ADDITIONAL INFORMATION ABOUT THIS TRIAL

([HTTPS://WWW.CLINICALTRIALS.GOV/CT2/SHOW/NCT05080764?TERM=ALA-ACV-CT014&DRAW=2&RANK=1](https://www.clinicaltrials.gov/ct2/show/NCT05080764?term=ALA-ACV-CT014&draw=2&rank=1))

ALA-AK-CT017 – CURRENTLY RECRUITING

This clinical trial aims at assessing the safety of Ameluz® for photodynamic therapy in the treatment of expanded field of actinic keratosis by investigating the concentration of Ameluz® in the blood.

There is no link to "additional information about this trial" for this study because the study is not listed on clinicaltrials.gov (where we link to the other studies).

ALA-AK-CT018 – STUDY COMPLETED

This clinical trial aimed to study the safety and tolerability of Ameluz® for photodynamic therapy in the treatment of the expanded field of actinic keratosis on face and scalp. The study was conducted in the US.

ADDITIONAL INFORMATION ABOUT THIS TRIAL

([HTTPS://WWW.CLINICALTRIALS.GOV/CT2/SHOW/NCT05060237?TERM=ALA-AK-CT018&DRAW=2&RANK=1](https://www.clinicaltrials.gov/ct2/show/NCT05060237?term=ALA-AK-CT018&draw=2&rank=1))

ALA-AK-CT019 – RECRUITMENT COMPLETE

This clinical trial aims to evaluate the safety, tolerability and efficacy of BF-200 ALA (Ameluz®) in the field-directed treatment of Actinic Keratosis (AK) on the extremities and neck/trunk with Photodynamic Therapy (PDT) using a RhodoLED® Lamp. The study is conducted in the US.

ADDITIONAL INFORMATION ABOUT THIS TRIAL

([HTTPS://WWW.CLINICALTRIALS.GOV/CT2/SHOW/NCT05662202?TERM=ALA-AK-&DRAW=2&RANK=1](https://www.clinicaltrials.gov/ct2/show/NCT05662202?term=ALA-AK-&draw=2&rank=1))

SERVICE

Imprint (<https://biofrontera.com/en/service/imprint>)

Disclaimer ([en/disclaimer-226.html](https://biofrontera.com/en/disclaimer-226.html))

Data Privacy Policy (<https://biofrontera.com/en/service/data-privacy-policy>)

ABOUT BIOFRONTERA

We have specialized in dermatology, as your skin's health is our concern. We aim to protect and heal your skin with our innovative medication for photodynamic therapy.

BIOFRONTERA AG © 2026 all rights reserved